The $30 million toe in the water

A new once-daily pill, HRS-7535, has demonstrated effectiveness similar to injectable GLP-1 drugs in lowering HbA1c over 16 weeks for adults with type 2 diabetes inadequately controlled on metformin.

The phase 2 trial findings suggest the oral medication could offer a conveneint alternative, though larger phase 3 studies are needed to confirm benefits and safety.

A groundbreaking new once-daily pill has demonstrated effectiveness comparable to GLP-1 receptor agonist injections in managing type 2 diabetes, according to a recent clinical trial.

Why 4,000 unsold units became the prize

In the United Kingdom alone, an estimated six million individuals live with type 2 diabetes, a chronic condition characterized by insufficient insulin production or impaired insulin utilization, resulting in elevated blood glucose levels.

Standard treatment frequently involves a combination of metformin and an SGLT2 inhibitor, both aimed at reducing blood sugar.

However, for some patients, GLP-1 receptor agonist injections like Ozempic are prescribed; these drugs have recently gained prominence for their weight-loss benefits alongside glycemic control.

An echo of Sydney's 2024 institutional buy-up

Scientists from Beijing Hospital propose that a novel oral medication could offer a more convenient alternative.

Their research, published in JAMA Network Open, evaluated a drug designated HRS-7535 among 194 adults with type 2 diabetes whose condition remained inadequately controlled with metformin monotherapy.

Over a 16-week period, the once-daily pill-which also belongs to the GLP-1 receptor agonist class-produced significant declines in HbA1c, reflecting average blood glucose.

Who is the unnamed buyer?

Participants were randomly allocated to receive either placebo or daily doses of 15mg, 30mg, 60mg, or 90mg of HRS-7535.

The placebo group experienced an HbA1c reduction of 0.25 percentage points.

Contrastingly, the trated groups saw reductions of 1.19% (15mg), 1.59% (30mg), 1.82% (60mg), and 1.64% (90mg).

Tehran's two-track response

These improvements are on par with or exceed the typical 1.0% to 1.5% HbA1c reduction observed with conventional injectable GLP-1 drugs.

Notably, nearly two-thirds of patients in the 60mg cohort attained HbA1c levels below 7.0%-a key therapeutic target to mitigate the risk of severe diabetic complications.

According to Diabetes UK, even modestly elevated HbA1c increases susceptibility to serious health issues, including cardiovascular events such as heart attack and stroke, chronic kidney disease, respiratory problems, neuropathy, musculoskeletal pain, vision loss, and foot infections.

A familiar pattern from the 2019 crash

The findings should be interpreted cautiously, however, as this constitutes a phase 2 trial, indicating that HRS-7535 remains in early-stage development with limited long-term safety data.

Some participants reported adverse events like nausea, diarrhea, and vomiting, though these were predominantly mild in severity.

The researchers advocate advancing to a phase 3 trial involving a larger, more diverse population to comprehensively assess the drug's risk-benefit profile.